Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Heart Failure Reviews
Erschienen in: Heart Failure Reviews 3/2016

29.01.2016

The right ventricle and pulmonary hypertension

verfasst von: Mariëlle C. van de Veerdonk, Harm J. Bogaard, Norbert F. Voelkel

Erschienen in: Heart Failure Reviews | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

In patients with pulmonary hypertension (PH), the primary cause of death is right ventricular (RV) failure. Improvement in RV function is therefore one of the most important treatment goals. In order to be able to reverse RV dysfunction and also prevent RV failure, a detailed understanding of the pathobiology of RV failure and the underlying mechanisms concerning the transition from a pressure-overloaded adapted right ventricle to a dilated and failing right ventricle is required. Here, we propose that insufficient RV contractility, myocardial fibrosis, capillary rarefaction, and a disturbed metabolism are important features of a failing right ventricle. Furthermore, an overview is provided about the potential direct RV effects of PH-targeted therapies and the effects of RV-directed medical treatments.
Literatur
1.
2.
3.
Pasque MK, Trulock EP, Cooper JD et al (1995) Single lung transplantation for pulmonary hypertension. Single institution experience in 34 patients. Circulation 92:2252–2258PubMedCrossRef
4.
Reesink HJ, Marcus JT, Tulevski II et al (2007) Reverse right ventricular remodeling after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: utility of magnetic resonance imaging to demonstrate restoration of the right ventricle. J Thorac Cardiovasc Surg 133:58–64PubMedCrossRef
5.
Oakley C (1988) Importance of right ventricular function in congestive heart failure. Am J Cardiol 62:14A–19APubMedCrossRef
6.
Sandoval J, Bauerle O, Palomar A et al (1994) Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 89:1733–1744PubMedCrossRef
7.
D’Alonzo GE, Barst RJ, Ayres SM et al (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115:343–349PubMedCrossRef
8.
Fuster V, Steele PM, Edwards WD et al (1984) Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70:580–587PubMedCrossRef
9.
Hopkins WE, Ochoa LL, Richardson GW, Trulock EP (1996) Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 15:100–105PubMed
10.
11.
12.
13.
van de Veerdonk MC, Marcus JT, Bogaard HJ, Vonk Noordegraaf A (2015) Cardiac MRI and PET scanning in right ventricular failure. In: Voelkel NF, Schranz D (eds) The right ventricle in health and disease, 1st edn. Springer, New York, pp 265–281
14.
15.
Mauritz GJ, Vonk-Noordegraaf A, Kind T et al (2012) Pulmonary endarterectomy normalizes interventricular dyssynchrony and right ventricular systolic wall stress. J Cardiovasc Magn Reson 12(14):5. doi:10.​1186/​1532-429X-14-5 CrossRef
16.
17.
Hinderliter AL, Willis PW, Long WA et al (2003) Frequency and severity of tricuspid regurgitation determined by Doppler echocardiography in primary pulmonary hypertension. Am J Cardiol 91(1033–7):A9
18.
19.
20.
van Wolferen SA, Marcus JT, Boonstra A et al (2007) Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 28:1250–1257PubMedCrossRef
21.
Hagger D, Condliffe R, Woodhouse N et al (2009) Ventricular mass index correlates with pulmonary artery pressure and predicts survival in suspected systemic sclerosis-associated pulmonary arterial hypertension. Rheumatology (Oxford) 48:1137–1142. doi:10.​1093/​rheumatology/​kep187 CrossRef
22.
Hopkins WE, Waggoner AD (2002) Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome. Am J Cardiol 89:34–38PubMedCrossRef
23.
24.
Schranz D, Rupp S, Müller M et al (2013) Pulmonary artery banding in infants and young children with left ventricular dilated cardiomyopathy: a novel therapeutic strategy before heart transplantation. J Heart Lung Transplant 32:475–481. doi:10.​1016/​j.​healun.​2013.​01.​988 PubMedCrossRef
25.
Brimouille S, Wauthy P, Ewalenko P et al (2003) Single-beat estimation of right ventricular end-systolic pressure–volume relationship. Am J Physiol Heart Circ Physiol 284:H1625–H1630CrossRef
26.
Suga H, Sagawa K, Shoukas AA (1973) Load independence of the instantaneous pressure–volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. Circ Res 32:314–322PubMedCrossRef
27.
28.
Tedford RJ, Mudd JO, Girgis RE et al (2013) Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension. Circ Heart Fail 6:953–963PubMedCrossRef
29.
Kuehne T, Yilmaz S, Steendijk P et al (2004) Magnetic resonance imaging analysis of right ventricular pressure–volume loops: in vivo validation and clinical application in patients with pulmonary hypertension. Circulation 110:2010–2016PubMedCrossRef
30.
Spruijt OA, de Man FS, Groepenhoff H et al (2015) The effects of exercise on right ventricular contractility and right ventricular–arterial coupling in pulmonary hypertension. Am J Respir Crit Care Med 191:1050–1057. doi:10.​1164/​rccm.​201412-2271OC PubMedCrossRef
31.
Lau EM, Chemla D, Godinas L et al (2015) Loss of vascular distensibility during exercise is an early hemodynamic marker of pulmonary vascular disease. Chest. doi:10.​1378/​chest.​15-0125
32.
Gan CT, Holverda S, Marcus JT et al (2007) Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients. Chest 132:11–17PubMedCrossRef
33.
34.
35.
Gomez-Arroyo J, Santos-Martinez LE, Aranda A et al (2014) Differences in right ventricular remodeling secondary to pressure overload in patients with pulmonary hypertension. Am J Respir Crit Care Med 189:603–606. doi:10.​1164/​rccm.​201309-1711LE PubMedCrossRef
36.
37.
McCann GP, Gan CT, Beek AM et al (2007) Extent of MRI delayed enhancement of myocardial mass is related to right ventricular dysfunction in pulmonary artery hypertension. Am J Roentgenol 188:349–355CrossRef
38.
39.
40.
Sanz J, Dellegrottaglie S, Kariisa M et al (2007) Prevalence and correlates of septal delayed contrast enhancement in patients with pulmonary hypertension. Am J Cardiol 100:731–735PubMedCrossRef
41.
Blyth KG, Syyed R, Chalmers J et al (2005) Pulmonary arterial pulse pressure and mortality in pulmonary arterial hypertension. Respir Med 101:2495–2501CrossRef
42.
Bandula S, White SK, Flett AS et al (2013) Measurement of myocardial extracellular volume fraction by using equilibrium contrast-enhanced CT: validation against histologic findings. Radiology 269:396–403. doi:10.​1148/​radiol.​13130130 PubMedCrossRef
43.
Guihaire J, Bogaard HJ, Flécher E et al (2013) Experimental models of right heart failure: a window for translational research in pulmonary hypertension. Semin Respir Crit Care Med 34:689–699. doi:10.​1055/​s-0033-1355444 PubMedCrossRef
44.
45.
46.
Bishop JE, Rhodes S, Laurent GJ et al (1994) Increased collagen synthesis and decreased collagen degradation in right ventricular hypertrophy induced by pressure overload. Cardiovasc Res 28:1581–1585PubMedCrossRef
47.
48.
Farahmand F, Hill MF, Singal PK (2004) Antioxidant and oxidative stress changes in experimental cor pulmonale. Mol Cell Biochem 260:21–29PubMedCrossRef
49.
Redout EM, Wagner MJ, Zuidwijk MJ et al (2007) Right-ventricular failure is associated with increased mitochondrial complex II activity and production of reactive oxygen species. Cardiovasc Res 75:770–781PubMedCrossRef
50.
Cucoranu I, Clempus R, Dikalova A et al (2005) NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97:900–907PubMedCrossRef
51.
Yet SF, Perrella MA, Layne MD et al (1999) Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice. J Clin Invest 103:R23–R29PubMedPubMedCentralCrossRef
52.
53.
Wong YY, Westerhof N, Ruiter G et al (2011) Systolic pulmonary artery pressure and heart rate are main determinants of oxygen consumption in the right ventricular myocardium of patients with idiopathic pulmonary arterial hypertension. Eur J Heart Fail 13:1290–1295. doi:10.​1093/​eurjhf/​hfr140 PubMedCrossRef
54.
55.
Vogel-Claussen J, Skrok J, Shehata ML et al (2011) Right and left ventricular myocardial perfusion reserves correlate with right ventricular function and pulmonary hemodynamics in patients with pulmonary arterial hypertension. Radiology 258:119–127. doi:10.​1148/​radiol.​10100725 PubMedPubMedCentralCrossRef
56.
Wong YY, Raijmakers PG, Knaapen P et al (2011) Supine-exercise-induced oxygen supply to the right myocardium is attenuated in patients with severe idiopathic pulmonary arterial hypertension. Heart 97:2069–2074. doi:10.​1136/​heartjnl-2011-300237 PubMedCrossRef
57.
van Wolferen SA, Marcus JT, Westerhof N et al (2008) Right coronary artery flow impairment in patients with pulmonary hypertension. Eur Heart J 29:120–127PubMedCrossRef
58.
59.
Sutendra G, Dromparis P, Paulin R et al (2013) A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J Mol Med (Berl) 91:1315–1327. doi:10.​1007/​s00109-013-1059-4 CrossRef
60.
61.
62.
May D, Gilon D, Djonov V et al (2008) Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. Proc Natl Acad Sci USA 105:282–287PubMedPubMedCentralCrossRef
63.
64.
65.
66.
Dávila-Román VG, Vedala G, Herrero P et al (2002) Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 40:271–277PubMedCrossRef
67.
Nagaya N, Goto Y, Satoh T, Uematsu M et al (1998) Impaired regional fatty acid uptake and systolic dysfunction in hypertrophied right ventricle. J Nucl Med 39:1676–1680PubMed
68.
69.
Oikawa M, Kagaya Y, Otani H et al (2005) Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. J Am Coll Cardiol 45:1849–1855PubMedCrossRef
70.
71.
Fang YH, Piao L, Hong Z et al (2012) Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle’s cycle. J Mol Med (Berl) 90:31–43. doi:10.​1007/​s00109-011-0804-9 CrossRef
72.
Piao L, Fang YH, Cadete VJ et al (2010) The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med (Berl) 88:47–60. doi:10.​1007/​s00109-009-0524-6 CrossRef
73.
Ventetuolo CE, Baird GL, Barr RG et al (2015) Higher estradiol and lower dehydroepiandrosterone-sulfate levels are associated with pulmonary arterial hypertension in men. Am J Respir Crit Care Med. doi:10.​1164/​rccm.​201509-1785OC
74.
75.
76.
77.
78.
79.
80.
81.
82.
Wood J, Albrecht M, Fisher A et al (2013) 17Beta-estradiol (E2) improves right ventricular (RV) function and exercise capacity in Su5416/Hypoxia (SuHx)-induced pulmonary hypertension (thoracic). Am J Respir Crit Care Med 187:A1028CrossRef
83.
84.
85.
Peacock AJ, Crawley S, McLure L et al (2014) Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study. Circ Cardiovasc Imaging. 7:107–114. doi:10.​1161/​CIRCIMAGING.​113.​000629 PubMedCrossRef
86.
87.
Jasmin JF, Cernacek P, Dupuis J (2003) Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension: response to chronic ETA receptor blockade. Clin Sci (Lond) 105:647–653CrossRef
88.
Nagendran J, Archer SL, Soliman D et al (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116:238–248PubMedCrossRef
89.
Borgdorff MA, Bartelds B, Dickinson MG et al (2012) Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle. Eur J Heart Fail 14:1067–1074. doi:10.​1093/​eurjhf/​hfs094 PubMedCrossRef
90.
Borgdorff MA, Bartelds B, Dickinson MG et al (2014) Sildenafil treatment in established right ventricular dysfunction improves diastolic function and attenuates interstitial fibrosis independent from afterload. Am J Physiol Heart Circ Physiol 307:H361–H369. doi:10.​1152/​ajpheart.​00843.​2013 PubMedCrossRef
91.
92.
93.
Velez-Roa S, Ciarka A, Najem B et al (2004) Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation 110:1308–1312PubMedCrossRef
94.
Holverda S, Gan CT, Marcus JT et al (2006) Impaired stroke volume response to exercise in pulmonary arterial hypertension. J Am Coll Cardiol 47:1732–1733PubMedCrossRef
95.
96.
97.
98.
99.
100.
101.
102.
Wang L, Li W, Yang Y et al (2015) Quantitative assessment of right ventricular glucose metabolism in idiopathic pulmonary arterial hypertension patients: a longitudinal study. Eur Heart J Cardiovasc Imaging. doi:10.​1093/​ehjci/​jev297
103.
Cucci AR, Kline JA, Lahm T (2015) Acute right ventricular failure. In: Voelkel NF, Schranz D (eds) The right ventricle in health and disease. Springer, New York, pp 161–205
104.
105.
106.
107.
Voelkel NF, Quaife RA, Leinwand LA et al (2006) Right ventricular function and failure: report of a national heart, lung, and blood institute working group on cellular and molecular mechanisms of right heart failure. Circulation 114:1883–1891PubMedCrossRef
108.
Voelkel NF, Bogaard HJ, Gomez-Arroyo J (2015) The need to recognize the pulmonary circulation and the right ventricle as an integrated functional unit: facts and hypotheses (2013 Grover Conference series). Pulm Circ 5:81–89. doi:10.​1086/​679702 PubMedPubMedCentralCrossRef
109.
110.
111.
Thum T, Borlak J (2000) Gene expression in distinct regions of the heart. Lancet 355:979–983PubMedCrossRef
112.
113.
114.
115.
Metadaten
Titel
The right ventricle and pulmonary hypertension
verfasst von
Mariëlle C. van de Veerdonk
Harm J. Bogaard
Norbert F. Voelkel
Publikationsdatum
29.01.2016
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 3/2016
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-016-9526-y

Weitere Artikel der Ausgabe 3/2016

Heart Failure Reviews 3/2016 Zur Ausgabe

OriginalPaper

Severe pulmonary arterial hypertension: stratification of medical therapies, mechanical support, and lung transplantation

OriginalPaper

Chronic thromboembolic pulmonary hypertension: detection, medical and surgical treatment approach, and current outcomes

OriginalPaper

Molecular pathogenesis and current pathology of pulmonary hypertension

OriginalPaper

Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction

OriginalPaper

Pulmonary hypertension associated with lung diseases and hypoxemia

OriginalPaper

Classification and diagnosis of pulmonary hypertension

Neu im Fachgebiet Kardiologie

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

10.05.2024 Periphere arterielle Verschlusskrankheit Nachrichten

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise